Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy

Inclusion Criteria:

* Male or female \> 18 years
* Histologically confirmed solid tumor.
* Subjects who have not received chemotherapy and / or radiotherapy in the last 3 months.
* Subject to initiate a chemotherapy (ie, cycle 1, day 1)
* The chemotherapy regimen should have an inherent risk of febrile neutropenia of 10-20%.
* Planning a minimum of 3 cycles chemotherapy.
* Adequate bone marrow reserve defined by: leukocytes ≥ 3,000 / mm3, platelets ≥ 100.000/mm3; neutrophils ≥ 1,500 / mm3.
* Adequate hepatic and renal function, defined by: bilirubin \<1.5 times the normal value, ALT and AST \<3 times the normal range (both can be elevated up to 5 times the normal value in patients with known liver metastases); creatinine \<1.5 times upper normal value
* ECOG ≤ 2.
* Informed consent

Exclusion Criteria:

* Patients under treatment with an investigational treatment.
* Active infection in the last 72 h before starting chemotherapy.
* Indication of chemotherapy dose intensity or chemotherapy included in the risk rating of febrile neutropenia \<10% or \>20%.
* Patients with concomitant chemoradiotherapy.
* Patients being treated with biological drugs in monotherapy.
* Any other condition causing neutropenia.
* History of bone marrow transplant or stem cells.